Cullinan Therapeutics outlines fourth-quarter 2026 data plans across three T cell engager programs
The company plans data updates on CLN-978, velinotamig, and CLN-049 in autoimmune and oncology indications between November and December 2026.
Cullinan Therapeutics, Inc. issued a press release on September 24, 2026 outlining planned milestones for the fourth quarter of 2026, disclosed in a Form 8-K filed the same day under Item 7.01 and Item 8.01.
For CLN-978, a CD19xCD3 T cell engager, Cullinan plans to disclose multi-dose and single target dose regimen results from Phase 1 trials in patients with treatment-refractory moderate to severe systemic lupus erythematosus, difficult-to-treat rheumatoid arthritis, and treatment-refractory moderate to severe Sjögren's disease, with that data expected in December.1
For velinotamig, a BCMAxCD3 T cell engager, Cullinan plans to present multi-dose regimen data from the Phase 1 dose escalation trial in SLE patients, run by Chongqing Genrix Biopharmaceutical Co., Ltd. in China, at a poster session during the American College of Rheumatology Convergence 2026 meeting in November.1 The filing specifies this session will take place on November 8, 2026, from 10:30 a.m. to 12:30 p.m. ET.1
For CLN-049, an FLT3xCD3 T cell engager being studied in relapsed/refractory acute myeloid leukemia, the company plans to share updated data from the dose escalation portion of its ongoing Phase 1 trial in December.1
CEO Nadim Ahmed said in the release that Cullinan looks forward to rapidly progressing the CLN-049 program and initiating a potentially registrational Phase 2 study following a recent successful meeting with the FDA.1 He also said the CD19- and BCMA-targeted programs represent what the company described as a differentiated approach to treating autoimmune diseases, aiming to address distinct disease drivers across a broad range of conditions.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.